
Multiple System Atrophy- Pipeline Insight, 2025
Description
DelveInsight’s, “Multiple System Atrophy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Multiple System Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Multiple System Atrophy: Overview
Multiple system atrophy (MSA) is a rare disease, affecting potentially 15,000 to 50,000 Americans, including people of all racial groups. The cause of MSA is unknown. The vast majority of cases are sporadic, meaning they occur at random. Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the central nervous system (which controls how a person moves), and the autonomic nervous system, which controls involuntary functions such as blood pressure or digestion.
The symptoms of MSA reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. MSA is one of a family of neurological disorders known as an atypical parkinsonian disorder. The initial symptoms can be difficult to distinguish from those of Parkinson's disease, and can include slowness of movement, tremor, or stiffness, clumsiness or lack of coordination, croaky, quivering voice, fainting or lightheadedness, bladder control problems, and many others.
There are two different types of MSA, which are categorized by the person’s most prominent symptoms when they’re evaluated by a doctor: a) Parkinsonian type MSA (MSA-P) which consists of primary symptoms similar to Parkinson's disease (such as slowness of movement, stiffness, and tremor) along with problems with balance, coordination, and autonomic nervous system dysfunction (such as urinary problems, sweating abnormalities, and digestion difficulties). b) Cerebellar type MSA (MSA-C) is associated with balance and coordination problems (ataxia), difficulty swallowing, speech problems or a quivering voice, and abnormal eye movements.
Diagnosing MSA can be difficult, particularly in the early stages because many of the features are similar to those observed in Parkinson's disease. In addition to taking a person’s medical and family history and performing a neurological examination, a doctor may order tests to support the diagnosis. These tests might include- Autonomic testing (such as blood pressure and heart rate control), Assessment of bladder function, Magnetic resonance imaging (MRI) may identify changes that suggest MSA or rule out other causes of the symptoms, Positron emission tomography (PET) scans to monitor metabolic function in specific parts of the brain, and Dopamine transporter (DaT) scans can assess the distribution and activity of dopamine in the brain.
Currently, there are no treatments to stop or slow the progression of MSA, and there is no cure. However, there are treatments to help people cope with the symptoms. Medications like levodopa may help improve motor function, Botulinum toxin injections to ease abnormal muscle postures, medicines to help with the bladder control and certain sleep problems are used. While therapies include Speech therapy that may help identify strategies to address swallowing difficulties and Physical therapy helps maintain mobility, reduce contractures, and decrease muscle spasms and abnormal posture.
""Multiple System Atrophy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple System Atrophy pipeline landscape is provided which includes the disease overview and Multiple System Atrophy treatment guidelines. The assessment part of the report embraces, in depth Multiple System Atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple System Atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Multiple System Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Multiple System Atrophy Emerging Drugs
Further product details are provided in the report……..
Multiple System Atrophy: Therapeutic Assessment
This segment of the report provides insights about the different Multiple System Atrophy drugs segregated based on following parameters that define the scope of the report, such as:
Multiple System Atrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Multiple System Atrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple System Atrophy drugs.
Multiple System Atrophy Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Multiple System Atrophy: Overview
Multiple system atrophy (MSA) is a rare disease, affecting potentially 15,000 to 50,000 Americans, including people of all racial groups. The cause of MSA is unknown. The vast majority of cases are sporadic, meaning they occur at random. Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the central nervous system (which controls how a person moves), and the autonomic nervous system, which controls involuntary functions such as blood pressure or digestion.
The symptoms of MSA reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. MSA is one of a family of neurological disorders known as an atypical parkinsonian disorder. The initial symptoms can be difficult to distinguish from those of Parkinson's disease, and can include slowness of movement, tremor, or stiffness, clumsiness or lack of coordination, croaky, quivering voice, fainting or lightheadedness, bladder control problems, and many others.
There are two different types of MSA, which are categorized by the person’s most prominent symptoms when they’re evaluated by a doctor: a) Parkinsonian type MSA (MSA-P) which consists of primary symptoms similar to Parkinson's disease (such as slowness of movement, stiffness, and tremor) along with problems with balance, coordination, and autonomic nervous system dysfunction (such as urinary problems, sweating abnormalities, and digestion difficulties). b) Cerebellar type MSA (MSA-C) is associated with balance and coordination problems (ataxia), difficulty swallowing, speech problems or a quivering voice, and abnormal eye movements.
Diagnosing MSA can be difficult, particularly in the early stages because many of the features are similar to those observed in Parkinson's disease. In addition to taking a person’s medical and family history and performing a neurological examination, a doctor may order tests to support the diagnosis. These tests might include- Autonomic testing (such as blood pressure and heart rate control), Assessment of bladder function, Magnetic resonance imaging (MRI) may identify changes that suggest MSA or rule out other causes of the symptoms, Positron emission tomography (PET) scans to monitor metabolic function in specific parts of the brain, and Dopamine transporter (DaT) scans can assess the distribution and activity of dopamine in the brain.
Currently, there are no treatments to stop or slow the progression of MSA, and there is no cure. However, there are treatments to help people cope with the symptoms. Medications like levodopa may help improve motor function, Botulinum toxin injections to ease abnormal muscle postures, medicines to help with the bladder control and certain sleep problems are used. While therapies include Speech therapy that may help identify strategies to address swallowing difficulties and Physical therapy helps maintain mobility, reduce contractures, and decrease muscle spasms and abnormal posture.
""Multiple System Atrophy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple System Atrophy pipeline landscape is provided which includes the disease overview and Multiple System Atrophy treatment guidelines. The assessment part of the report embraces, in depth Multiple System Atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple System Atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Multiple System Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve Multiple System Atrophy.
This segment of the Multiple System Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Multiple System Atrophy Emerging Drugs
- Ampreloxetine: Theravance Biopharma
- ATH434: Alterity Therapeutics
- AB-1005: AskBio
Further product details are provided in the report……..
Multiple System Atrophy: Therapeutic Assessment
This segment of the report provides insights about the different Multiple System Atrophy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Multiple System Atrophy
- There are approx. 20+ key companies which are developing the therapies for Multiple System Atrophy. The companies which have their Multiple System Atrophy drug candidates in the most advanced stage, i.e. Phase III include, Theravance Biopharma.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Multiple System Atrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Multiple System Atrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple System Atrophy drugs.
Multiple System Atrophy Report Insights
- Multiple System Atrophy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Multiple System Atrophy drugs?
- How many Multiple System Atrophy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multiple System Atrophy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Multiple System Atrophy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Multiple System Atrophy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Theravance Biopharma
- Alterity Therapeutics
- AskBio
- Kainos Medicines
- CORESTEM, Inc.
- ProMIS Neuroscience
- H. Lundbeck A/S
- Ampreloxetine
- ATH434
- AB-1005
- KM-819
- Lu AF82422
- CE111BR16
- PMN442
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Multiple System Atrophy: Overview
- Introduction
- Symptoms
- Pathophysiology
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Multiple System Atrophy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Ampreloxetine: Theravance Biopharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ATH434: Alterity Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- AB-1005: AskBio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Product Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Multiple System Atrophy Key Companies
- Multiple System Atrophy Key Products
- Multiple System Atrophy- Unmet Needs
- Multiple System Atrophy- Market Drivers and Barriers
- Multiple System Atrophy- Future Perspectives and Conclusion
- Multiple System Atrophy Analyst Views
- Multiple System Atrophy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.